News for Edwards Lifesciences Corporation (EW)

Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA

\nEdwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2025 after the market closes on Wednesday April 23, 202

Edwards Lifesciences Corporation (NYSE: EW) today announced the company's SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter trea

Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A copy of the same can be downloaded here. Select Growth primarily targets U.S. companies that are leading the way in crucial areas of positive structural transformation within the economy. The fund returned 8.8% (net) in the fourth […]

Despite a solid Q4 earnings beat, Edwards Lifesciences' shares remain undervalued with a reduced P/E multiple of 33x. Read why EW stock is a Buy.

PR NewswireGALWAY, Ireland and WASHINGTON, March 9, 2025 CRT 2025 Late Breaking Science features largest head-to-head randomized control TAVR trial to prim

Looking into the current session, Edwards Lifesciences Inc. EW shares are trading at $71.65, after a 0.28% spike. Moreover, over the past month, the stock spike...

Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen 45th Annual Health Care Conference on Tuesday, Mar. 4, 2025.

EW stock is on investors' radars due to the promising structural heart opportunities following the divestment of the Critical Care arm.

Earnings Call Insights: Edwards Lifesciences Corporation (NYSE:EW) Q4 2024Management ViewCEO Bernard Zovighian highlighted a strong Q4 2024 performance with...

Edwards Lifesciences Corporation (NYSE:EW) Q4 2024 Earnings Conference Call February 11, 2025 5:00 PM ETCompany ParticipantsMark Wilterding - Senior Vice...

Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Stocks Analysis by Christine Short covering: S&P 500, Microsoft Corporation, McDonald’s Corporation, Gilead Sciences Inc. Read Christine Short's latest article on Investing.com

Besides Wall Street's top -and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.

Stock Market today | Share Market Live Updates - Find here all the live updates related to Sensex, Nifty, BSE, NSE, share prices and Indian stock markets for 4 February 2025.

Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business changes for 2025.

Edwards Lifesciences (NYSE: EW) stock rises after Stifel upgrades to Buy, citing potential for TAVR growth acceleration in 2025. Read more here.

Favorable hospitalization trend, strong adoption of transcatheter heart valves and improved procedural volume are expected to have aided EW in the fourth quarter.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...